Nicoleta Dima Luminiţa Gina Vâţă Elena Rezuş Anca Trifan

Abstract

This is the case of a 64-year old hypertensive, diabetic patient, known to have liver cirrhosis, with a history of pulmonary thromboembolism, with permanent electrical cardiac stimulation, who was hospitalized for a newly diagnosed giant popliteal hematoma. The patient is currently discharged and following oral anticoagulant treatment.

##plugins.themes.bootstrap3.article.details##

Keywords

liver cirrhosis, oral anticoagulant treatment, permanent electrical cardiac stimulation, type 2 diabetes mellitus, pulmonary thromboembolism

References
1. Zatonski WA, Sulkowska U, Manczuk M, et al. Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe. Eur Addict Res 2010; 16(4):193-201.
2. Kamath PS, Kim WR, Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 2007; 45(3):797-805.
3. Al Ghumlas AK, Abdel Gader AG, Al Faleh FZ. Haemostatic abnormalities in liver disease: could some haemostatic tests be useful as liver function tests? Blood Coagul Fibrinolysis. 2005; 16(5):329-35.
4. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365(2):147-156.
5. Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med 2007; 120(10):829-834.
6. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002; 17(6):677-681.
7. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409(6818):307-312.
8. Nishida T, Tsuji S, Tsujii M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol 2006; 101(1):70-75.
9. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30(3):734-743.
10. El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002; 122(7):1822-1828.
11. Del Vecchio Blanco C, Gentile S, Marmo R, Carbone L, Coltorti M. Alterations of glucose metabolism in chronic liver disease. Diabetes Res Clin Pract 1990; 8(1):29-36.
12. Roberts LN, Patel RK, Arya R. Haemostasis and thrombosis in liver disease. Br J Haematol 2010; 148(4):507-521.
13. Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G.. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost 2011; 37(3):267-74.
14. Moller S, Henriksen JH. Cirrhotic cadiomyopathy. J Hepatol 2010; 53(1):179-190.
How to Cite
Dima, N., Vâţă, L. G., Rezuş, E., & Trifan, A. (2015). Liver cirrhosis and the anticoagulant treatment – from guided indications to daily practice - case report. Archive of Clinical Cases, 2(1), Arch Clin Cases 2015; 2(1):36-41. https://doi.org/10.22551/2015.05.0201.10031
Section
Case Reports

How to Cite

Dima, N., Vâţă, L. G., Rezuş, E., & Trifan, A. (2015). Liver cirrhosis and the anticoagulant treatment – from guided indications to daily practice - case report. Archive of Clinical Cases, 2(1), Arch Clin Cases 2015; 2(1):36-41. https://doi.org/10.22551/2015.05.0201.10031